Global Security Newswire
Daily News on Nuclear, Biological & Chemical Weapons, Terrorism and Related Issues
NIAID Issues Contract For Advanced Work on Smallpox-Marburg Virus Vaccine
The U.S. National Institute of Allergy and Infectious Diseases has issued a contract to a Danish biotechnology firm to finance advanced research of experimental vaccines that could be used against both the Marburg and smallpox viruses (see GSN, May 9).
"This new contract will support the advanced development of candidate vaccine components and technologies that accelerate the immune response for use in post-event settings following the intentional release of pathogens that are considered a threat to public health," Bavarian Nordic stated in a Monday press release.
In the initial two years of the contract, the biotechnology firm is to assess multiple potential combinative Marburg and smallpox vaccines in laboratory experiments. The contract allows for an initial clinical study for the most promising vaccine candidate
The contract is worth $17.9 million if extended to its full five years (Bavarian Nordic release, June 18).
Separately, the National Institutes of Health branch issued a half-year research grant to Alabama-based Vaxin Inc. to assess a potential anthrax vaccine candidate, the Birmingham Business Journal reported on Monday.
In 2011, the Birmingham firm was awarded $21 million to continue work on its product (Birmingham Business Journal, June 18).
Oct. 21, 2013
The UNSCR 1540 Resource Collection examines implementation of United Nations Security Council Resolution 1540, which requires all states to implement measures aimed at preventing non-state actors from acquiring NBC weapons, related materials, and their means of delivery. It details implementation efforts in all of the regions and countries of the world to-date.
This article provides an overview of the United States’ historical and current policies relating to nuclear, chemical, biological and missile proliferation.